265 related articles for article (PubMed ID: 24172289)
1. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
2. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
He H; Mennone A; Boyer JL; Cai SY
Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
[TBL] [Abstract][Full Text] [Related]
3. Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells.
Alaca N; Özbeyli D; Uslu S; Şahin HH; Yiğittürk G; Kurtel H; Öktem G; Çağlayan Yeğen B
Turk J Gastroenterol; 2017 Nov; 28(6):476-484. PubMed ID: 29086715
[TBL] [Abstract][Full Text] [Related]
4. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation.
Sokolovic D; Nikolic J; Kocic G; Jevtovic-Stoimenov T; Veljkovic A; Stojanovic M; Stanojkovic Z; Sokolovic DM; Jelic M
Drug Chem Toxicol; 2013 Apr; 36(2):141-8. PubMed ID: 22385135
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
6. ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice.
Almishri W; Swain LA; D'Mello C; Le TS; Urbanski SJ; Nguyen HH
Front Immunol; 2021; 12():779119. PubMed ID: 35095853
[TBL] [Abstract][Full Text] [Related]
7. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Weerachayaphorn J; Luo Y; Mennone A; Soroka CJ; Harry K; Boyer JL
J Hepatol; 2014 Jan; 60(1):160-6. PubMed ID: 23978715
[TBL] [Abstract][Full Text] [Related]
8. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.
Ishizaki K; Iwaki T; Kinoshita S; Koyama M; Fukunari A; Tanaka H; Tsurufuji M; Sakata K; Maeda Y; Imada T; Chiba K
Eur J Pharmacol; 2008 Jan; 578(1):57-64. PubMed ID: 17888421
[TBL] [Abstract][Full Text] [Related]
10. ADAM10/17-dependent release of soluble c-Met correlates with hepatocellular damage.
Chalupský K; Kanchev I; Žbodáková O; Buryová H; Jiroušková M; Kořínek V; Gregor M; Sedláček R
Folia Biol (Praha); 2013; 59(2):76-86. PubMed ID: 23746173
[TBL] [Abstract][Full Text] [Related]
11. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
Pathil A; Warth A; Chamulitrat W; Stremmel W
J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
13. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.
Iruzubieta P; Goikoetxea-Usandizaga N; Barbier-Torres L; Serrano-Maciá M; Fernández-Ramos D; Fernández-Tussy P; Gutiérrez-de-Juan V; Lachiondo-Ortega S; Simon J; Bravo M; Lopitz-Otsoa F; Robles M; Ferre-Aracil C; Varela-Rey M; Elguezabal N; Calleja JL; Lu SC; Milkiewicz M; Milkiewicz P; Anguita J; Monte MJ; Marin JJG; López-Hoyos M; Delgado TC; Rincón M; Crespo J; Martínez-Chantar ML
JHEP Rep; 2021 Jun; 3(3):100276. PubMed ID: 33997750
[TBL] [Abstract][Full Text] [Related]
14. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
17. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro.
Zhu L; Shan LJ; Liu YJ; Chen D; Xiao XG; Li Y
J Dig Dis; 2014 Dec; 15(12):684-93. PubMed ID: 25214410
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
20. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
